正清风痛宁片治疗慢性肾炎的临床研究

Clinical Study on Zhengqing Fengtongning Tablet for Chronic Nephritis

采用分层随机分组、阳性药物对照设计方案，观察慢性肾炎１２０例。结果表明，正清风痛宁片治疗慢性肾炎之总缓解率、总有效率分别为３８．３％、７１．７％；治疗湿热瘀结证证候总缓解率、总有效率分别为５３．３％、８５．０％。与对照组比较，两组间证候总缓解率差异有显著性意义（Ｐ＜０．０５），而慢性肾炎总缓解率、总有效率与证候总有效率无显著性差异（Ｐ＞０．０５）。两药均能显著降低慢性肾炎患者的尿蛋白，减少尿中红细胞，组间差异无统计学意义（Ｐ＞０．０５）。两药能显著改善疾病主症，但对水肿、胸腹胀闷及腰痛以治疗药作用较优。正清风痛宁片治疗慢性肾炎疗程应为３个月及以上。其不良反应出现总频次６／６０（１０．０％），主要为皮疹和胃脘不适，临床用药安全性优于对照药。

One hundred and twenty cases of chronic nephritis were allocated to two groups:the treatment group (60,treated with Zhengqing Fengtongning Tablet) and the positive control group (60,treated with Wifordoside).The results showed that in the treatment group,the total improved rate and the total effective rate for chronic nephritis were 38.3% and 71.7% respectively,and those for the syndrome of stagnation of damp_heat were 53.3% and 85.0% respectively.As compared with the control group,only the differences of the total improved rate for the syndrome were significant(P<0.05).The content of urinary protein and the number of red blood cells in urine were decreased markedly but the differences between the two groups were not significant(P>0.05).The main symptoms were improved markedly in two groups,while the improvement of edema,chest and abdominal upset and lumbago was more marked in the treatment group.The treatment course of Zhengqing Fengtongning Tablet should be 3 months or more over,and the frequency of adverse reaction and toxic and side effects is 6/60(10.0%),mainly manifestated as skin eruption and gastric upset.Clinically,Zhengqing Fengtongning Tablet is more safe than the control medicine.